Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPramipexole dihydrochloride is a dopamine receptor agonist exhibiting selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits negligible affinity for D1 and D5 receptors. Displays activity in the treatment of Parkinson's disease.
Pramipexole dihydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 284.25 |
Formula | C10H17N3S.2HCl |
Storage | Desiccate at RT |
Purity | ≥99% (HPLC) |
CAS Number | 104632-25-9 |
PubChem ID | 119569 |
InChI Key | QMNWXHSYPXQFSK-KLXURFKVSA-N |
Smiles | NC(S2)=NC1=C2C[C@@H](NCCC)CC1.Cl.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 28.43 | 100 | |
DMSO | 28.43 | 100 |
The following data is based on the product molecular weight 284.25. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.52 mL | 17.59 mL | 35.18 mL |
5 mM | 0.7 mL | 3.52 mL | 7.04 mL |
10 mM | 0.35 mL | 1.76 mL | 3.52 mL |
50 mM | 0.07 mL | 0.35 mL | 0.7 mL |
References are publications that support the biological activity of the product.
Mierau et al (1995) Pramipexole binding and activation of cloned and expressed DA D2, D3 and D4 receptors. Eur.J.Pharmacol. 290 29 PMID: 7664822
If you know of a relevant reference for Pramipexole dihydrochloride, please let us know.
Keywords: Pramipexole dihydrochloride, Pramipexole dihydrochloride supplier, dopamine, D3, agonists, Parkinsons, Disease, antiparkinson, parkinson's, dopaminergic, Receptors, 4174, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Pramipexole dihydrochloride include:
Fen et al (2023) Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson's disease. Acta Pharmacol Sin 44 32-43 PMID: 35896696
Wang et al (2015) A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in DA D2 and D3 receptor agonist-induced autophagy activation. J Exp Bot 11 2057 PMID: 26649942
Bonito-Oliva et al (2014) A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions. Front Behav Neurosci 8 290 PMID: 25221486
Do you know of a great paper that uses Pramipexole dihydrochloride from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Pramipexole dihydrochloride and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.